Obergan (Rivaroxaban)

Rivaroxaban is an oral anticoagulant that acts on the coagulation cascade to reduce clot formation in several clinical settings.

• Atrial fibrillation: reduces the risk of stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
• Deep‑vein thrombosis (DVT) treatment: treats acute DVT and helps prevent recurrence.
• Pulmonary embolism (PE) treatment: treats acute PE and helps prevent recurrence.
• Post‑operative thromboprophylaxis: prevents venous thromboembolism after hip or knee replacement surgery.
• Secondary prevention after myocardial infarction: lowers the risk of subsequent cardiovascular events.

• Rivaroxaban selectively inhibits Factor Xa, a key enzyme in the conversion of prothrombin to thrombin within the coagulation cascade. By blocking this step, it reduces thrombin generation and limits fibrin clot formation, providing anticoagulant activity without the need for routine laboratory monitoring.

Rivaroxaban may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects

• Minor gastrointestinal discomfort or dyspepsia.
• Mild bruising or superficial skin ecchymoses.
• Transient headache.
• Nausea.
• Low‑grade elevation of liver enzymes.

Serious or Rare Side Effects

• Major bleeding, including intracranial or gastrointestinal hemorrhage.
• Hemorrhagic stroke.
• Spontaneous retroperitoneal bleed.
• Severe allergic reactions such as anaphylaxis.
• Liver injury with marked enzyme elevation.
• Thrombocytopenia.

When prescribing rivaroxaban, clinicians should assess individual risk factors and monitor patients for signs of bleeding.

• Renal impairment: adjust dose or avoid use in severe renal dysfunction.
• Hepatic disease: avoid in patients with significant liver disease.
• Concomitant antiplatelet therapy: increase bleeding risk; use caution.
• History of gastrointestinal ulcer or bleeding: monitor closely.
• Pregnancy and lactation: avoid unless clearly needed; discuss risks.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Rivaroxaban interacts with several drug classes that can modify its anticoagulant effect, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase plasma concentrations.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may substantially reduce efficacy.
• Combined use with other anticoagulants or antiplatelet agents: high risk of serious bleeding.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may modestly raise rivarox‑an levels.
• NSAIDs and selective COX‑2 inhibitors: increase gastrointestinal bleeding risk.
• P‑gp inhibitors (e.g., amiodarone, verapamil): can elevate drug exposure.
• Herbal supplements such as St John’s wort: may reduce anticoagulant effect.
• Antifungal azoles (e.g., fluconazole): may increase exposure modestly.